Sales Growth Overview
Novo Nordisk has recently announced a remarkable 12% increase in sales measured in Danish kroner, alongside a substantial 15% rise when factoring in constant exchange rates (CER) during the first nine months of 2025. The company's performance has showcased its resilience and adaptability, positioning it as a leader in the healthcare industry.
Operating Profit and Sales Highlights
The operating profit for Novo Nordisk has climbed by 5% in Danish kroner, reaching DKK 95.9 billion. When looking at constant exchange rates, this figure reflects a 10% increase. Notably, one-time restructuring costs of around DKK 9 billion impacted these figures, but without them, the profit would have surged by 15% in kroner and 21% at CER. This transformation is focused on streamlining operations to reinvest in growth.
US and International Sales Performance
Sales from the US operations saw a 12% growth in kroner, translating to 15% at CER. This growth was buoyed by adjustments in gross-to-net sales. Meanwhile, International Operations demonstrated a healthy growth rate, achieving a 13% increase in kroner and 16% at CER. This showcases the company's strong global market position.
Growth in Diabetes and Obesity Care
Within the segments of Diabetes and Obesity care, sales rose by 12%, totaling DKK 215.7 billion (15% at CER). The growth was heavily influenced by the 37% surge in Obesity care sales, which reached DKK 59.9 billion (41% at CER). Furthermore, sales from GLP-1 diabetes treatments grew by 7% in kroner and 10% at CER, highlighting the demand and effectiveness of these innovative treatments. Additionally, rare disease sales also saw a commendable growth of 10% in kroner and 13% at CER.
Research and Development Progress
Novo Nordisk has made significant strides in its R&D pipeline. The company recently announced the US FDA's approval of an indication for Wegovy for treating MASH conditions. Furthermore, they have plans to acquire Akero Therapeutics, Inc., which promises a robust phase 3 FGF21 analogue for MASH. The company has also submitted Mim8 for regulatory approval within rare blood disorders and initiated the phase 3 development of cagrilintide, potentially the first amylin monotherapy for weight management.
2025 Outlook and Strategic Decisions
Looking ahead, Novo Nordisk anticipates sales growth between 8-11% at CER for the full year, with operating profit growth expected between 4-7%, factoring a negative impact of around DKK 8 billion from their company-wide transformation. The narrowing guidance reflects the changing expectations for the growth of their GLP-1 treatments.
Corporate Developments
In a significant governance move, Novo Nordisk's Board of Directors plans to hold an extraordinary general meeting to elect new members, scheduled for mid-November 2025. Such changes underline the company’s commitment to evolving and adapting its leadership in response to market dynamics.
Mike Doustdar, the president and CEO, shared insights on the operational improvements driven by the company’s transformation. He emphasized the aim to expand treatment options for a larger patient base, especially in obesity management. Doustdar's optimistic view stems from the company's strong sales performance during the year.
About Novo Nordisk
Founded in 1923, Novo Nordisk stands out as a leading global healthcare company headquartered in Denmark. Their mission revolves around defeating serious chronic diseases, particularly diabetes, through pioneering scientific advancements and expanding access to essential medications. With approximately 78,500 employees operating across 80 countries, the company markets its products in around 170 nations. Novo Nordisk's B shares are traded on Nasdaq Copenhagen, while its ADRs are listed on the New York Stock Exchange.
Frequently Asked Questions
What were Novo Nordisk's sales growth rates for 2025?
Sales increased by 12% in Danish kroner and 15% at constant exchange rates for the first nine months of 2025.
What impacted the operating profit of Novo Nordisk?
Operating profit increased by 5% in Danish kroner, impacted by one-off restructuring costs of around DKK 9 billion.
How did the US and International Operations perform?
US operations sales rose by 12% in kroner; International Operations sales grew by 13% in kroner.
What recent R&D developments did Novo Nordisk announce?
Novo Nordisk announced FDA approval for Wegovy in MASH and plans to acquire Akero Therapeutics.
What is the forecast growth for Novo Nordisk in 2025?
The company expects sales growth of 8-11% and operating profit growth of 4-7% for 2025.
